EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis

Adithya Jayaprakash Kamath, Alda Sara Chandy, Aina Ann Joseph, Jaggiah N Gorantla, Asawari Dilip Donadkar, Lekshmi R Nath, Javad Sharifi-Rad, Daniela Calina

EXCLI Journal · 13.12.2023 · 22 · 1311-1329

DOI: 10.17179/excli2023-6590 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 13.12.2023. Verfasst von Adithya Jayaprakash Kamath und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Embelin, a natural para-benzoquinone product, is derived from plants of the Embelia genus, particularly Embelia ribes Burm.f. A staple in traditional medicinal formulations for centuries, Embelin's pharmacological actions are attributed to the hydroxyl benzoquinone present in its structure. Its therapeutic potential is bolstered by unique physical and chemical properties. Recently, Embelin, recognized as a non-peptidic, cell-permeable small inhibitor of the X-linked inhibitor of apoptosis protein (XIAP), has garnered significant attention for its anticancer activity. It demonstrates various anticancer mechanisms, such as apoptosis induction, cell cycle arrest, and autophagy, in different cancer types. Additionally, Embelin modulates several signal transduction pathways, including NF-κB, PI3Kinase/AKT, and STAT3, effectively inhibiting the proliferation of diverse cancer cell lines. This literature review illuminates the anticancer potential of Embelin, detailing its mechanisms of action and prospective clinical applications, based on relevant scientific literature from the past decade sourced from various electronic databases.

Schlagwörter

Stichwörter der Autor:innen

Embelia ribesEmbelinantitumor mechanismsbioavailabilitycancertoxicity of Embelin

Autor:innen und Institutionen

  • Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.
  • Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.
  • Department of Chemistry, Wayne State University, Detroit-48202, Michigan, USA.
  • Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador.
  • Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Zitieren

APA

Kamath, A. J., Chandy, A. S., Joseph, A. A., Gorantla, J. N., Donadkar, A. D., Nath, L. R., Sharifi-Rad, J., & Calina, D. (2023). Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis. EXCLI Journal, 22, 1311-1329. https://doi.org/10.17179/excli2023-6590

Vancouver

Kamath AJ, Chandy AS, Joseph AA, Gorantla JN, Donadkar AD, Nath LR, et al. Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis. EXCLI Journal. 2023;22:1311-1329. doi:10.17179/excli2023-6590

BibTeX
@article{Kamath2023,
  author = {Kamath, Adithya Jayaprakash and Chandy, Alda Sara and Joseph, Aina Ann and Gorantla, Jaggiah N and Donadkar, Asawari Dilip and Nath, Lekshmi R and Sharifi-Rad, Javad and Calina, Daniela},
  title = {Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis},
  journal = {EXCLI Journal},
  year = {2023},
  volume = {22},
  pages = {1311--1329},
  doi = {10.17179/excli2023-6590}
}
Kostenlos starten →